Search Results 11-20 of 17379 for GLP-1 secretion

  1. Evaluation of the changes in glycemic and physiologic parameters (sleep, cardioadapatbility parameters) in non-diabetic patients being treated for obesity with GLP1 Agonist and GLP-1/ GIP agonist medications. - Mayo Clinic

    ... GLP1 Agonist and GLP-1/ GIP agonist medications. Print details. Share ... It is proposed that participants will wear the devices for a period of 28 days before ...

  2. rs7903146 genotype on islet GLP-1 production in humans - Mayo Clinic

    The purpose of this study is to determine the contribution of islet GLP-1 to islet function in people with and without diabetes-associated genetic variation in ...

  3. A Study To Determine The Effects Of Blocking The Receptors Of GLP-1 On Appetite After Bariatric Surgery - Mayo Clinic

    A Study To Determine The Effects Of Blocking The Receptors Of GLP-1 On Appetite After Bariatric Surgery · Overview · Participation eligibility · Participating Mayo ...

  4. Examining the impact of GLP-1 receptor agonist use on quality of bowel preparation for colonoscopy - Mayo Clinic

    Adequate bowel preparation is essential to facilitate examination of the mucosal surface and detect adenomas during colonoscopy. Prior research and clinical ...

  5. Preoperative Gastric Content With Ultrasound Assessment in Patients Taking GLP1 Agonists - Mayo Clinic

    ... 1 (GLP-1) agonist medications compared to patients who do not take GLP-1 agonists. Participation eligibility. Participant eligibility includes age, gender ...

  6. Islet GLP-1 in Prediabetes - Clinical Trials

    The purpose of this study is to determine the contribution of islet GLP-1 to islet function in prediabetes. Participation eligibility. Participant ...

  7. Diabetes Clinical Trials - Mayo Clinic Research

    The goal of this study is to determine the role of postprandial glucagon suppression and insulin secretion ... 1 diabetes mellitus. ... GLP-1 is a hormone made by ...

  8. GLP-1RA and thyroid cancer: New study suggests detection bias, not causation - Mayo Clinic

    Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are cornerstone therapies for type 2 diabetes, obesity and cardiovascular health.

  9. Diabetes treatment: Medications for type 2 diabetes - Mayo Clinic

    Tirzepatide (Mounjaro), a similar kind of medicine called a dual-acting GLP-1/GIP agonist. Action. Cause the release of insulin as blood sugar levels are rising ...

  10. Type 2 Diabetes Clinical Trials - Mayo Clinic Research

    The hypothesis of this study is that increased glucagon-like peptide-1 (GLP-1) secretion explains the amelioration in insulin secretion after Roux-en-Y Gastric ...